SCHEMBL4900157

SCHEMBL4900157

Nc1ncnc2c1sc1nc(-c3ccc(F)cc3)cc(-c3ccccc3)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.62
PTK2B Q14289 2/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
LIMK1 P53667 6/20 0.58
KDM4E B2RXH2 3/20 0.56
MAPT P10636 2/20 0.56
PPARG P37231 3/20 0.49
NR2E3 Q9Y5X4 3/20 0.49
NCOR2 Q9Y618 3/20 0.49
MCL1 Q07820 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CLK1 P49759 3/20 0.48
CDC7 O00311 3/20 0.48
DBF4 Q9UBU7 3/20 0.48
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
POLB P06746 1/20 0.47
ADORA2A P29274 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899938 0.93 LIMK1 (0.66) HPGDPTK2BCYP1A2CYP2C9CYP2C19
SCHEMBL4899880 0.89 KDM4E (0.62) HPGDPTK2BCYP1A2CYP2C9CYP2C19
SCHEMBL4902783 0.86 PPARG (0.64) HPGDPTK2BCYP1A2CYP2C9CYP2C19
SCHEMBL259291 0.81 CDC7 (0.66) HPGDLIMK1KDM4EMAPTPPARG
SCHEMBL4905558 0.81 CDC7 (0.66) HPGDLIMK1KDM4EMAPTCLK1
SCHEMBL4894356 0.81 HPGD (0.58) HPGDLIMK1KDM4EMAPTNPSR1
SCHEMBL4903351 0.81 CDC7 (0.64) HPGDLIMK1MAPTCLK1CDC7
SCHEMBL4899003 0.80 MEN1 (0.59) LIMK1KDM4EMAPTCLK1CDC7
SCHEMBL4899997 0.79 MAPT (0.50) HPGDLIMK1KDM4EMAPTNPSR1
SCHEMBL12969725 0.78 LIMK1 (0.51) LIMK1MAPTCLK1CDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012131297-A1 PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE BAELL JONATHAN BAYLDON (AU) 2012-10-04 WO disclosed
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses CYWIN CHARLES L 2008-01-10 US disclosed
US-7291733-B2 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-11-06 US disclosed
EP-1673374-A2 SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-06-28 EP disclosed
US-20050101601-A1 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-05-12 US disclosed
WO-2005035537-A2 SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101601-A1 Substituted tricyclic heterocycles and their uses LTC4S, NQO1, CBR3 HPGD 53/4885PTK2B 3409/4885CYP1A2 67/4885
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses LTC4S, NQO1, CBR3 HPGD 53/4885PTK2B 3409/4885CYP1A2 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.